Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center [DILIN DCC](U01)

The summary for the Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center [DILIN DCC](U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center [DILIN DCC](U01): The purpose of this Funding Opportunity is to invite an application (through a limited competition) for continued support of the Data Coordinating Center (DCC) for the Drug Induced Liver Injury Network (DILIN). Drug-induced liver injury is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease.
Federal Grant Title: Limited Competition for the Continuation of the Drug Induced Liver Injury Network Data Coordinating Center [DILIN DCC](U01)
Federal Agency Name: National Institutes of Health
Grant Categories: Food and Nutrition Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DK-13-502
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.847
CFDA Descriptions: Diabetes, Digestive, and Kidney Diseases Extramural Research
Current Application Deadline: Feb 27, 2013
Original Application Deadline: Feb 27, 2013
Posted Date: Dec 12, 2012
Creation Date: Dec 12, 2012
Archive Date: Mar 30, 2013
Total Program Funding: $1,170,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards: 1
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Only institutions with the current Data Coordinating Center (DCC) for the Drug Induced Liver Injury Network are eligible to apply. Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Limited Competition for the Continuation of the Scientific Data Research Center (SDRC) for...
Limited Competition for the Continuation of Clinical Centers to Investigate the Pathogene...
Limited Competition for Continuation of the Integrated Islet Distribution Program (U24 Cli...
Limited Competition for the Continuation of the Urinary Stone Disease Research Network (US...
Limited Competition for the Continuation of the Urinary Stone Disease Research Network (US...
Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes
Molecular Therapy Core Centers
Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021 FederalGrants.com